Total amount: € 0,00
Official Journal of the Italian Society of Social Psychiatry
Indexed/Abstracted in: EMBASE, e-psyche, PsycINFO, Scopus
Online ISSN 1827-1731
Barzega G., Bogetto F., Maina G., Ravizza L.
Objective. Seroquel belongs to the newest generation of atypical antipsychotic drugs. Various multicentre-controlled double blind trials have shown it to be effective and well tolerated in patients diagnosed as suffering from acute exacerbations of chronic or subchronic schizophrenia. The Turin University Psychiatric Clinic took part in a multcentre, randomized double blind trial designed to discover optimum doses of Seroquel in the treatment of patients suffering from acute exacerbations of chronic or subchronic schizophrenia by comparing three different dose regimes (50 mg per diem, 150 mgx3 per diem and 225x2 per diem).
Methods. Six patients (two for each treatment cells), were treated in hospital for six weeks during which both their clinical symptoms and any adverse reactions or alterations in life-related parameters were carefully monitored.
Results. The findings confirmed the significant clinical efficacy of Seroquel in a dose of 450 mg per diem which began to have an effect on positive symptoms from Week II and on negative symptoms from Week III. No significant adverse effects were encountered and no extrapyramidal sideeffects. In one case the drug was administered for over 4 years, confirming its long-term effectiveness, since no acute reexacerbations ever recurred and the patient was able to achieve and maintain a satisfactory life-style.
Conclusions. In conclusion, however preliminary, the data presented have shown Seroquel to be effective and well tolerated in acute exacerbations of chronic or subchronic schizophrenia.